ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,502,403, issued on Dec. 23, was assigned to DILAFOR AB (Solna, Sweden).
"Tafoxiparin for the treatment of preeclampsia" was invented by Lena Degling-Wikingsson (Spanga, Sweden), Gunvor Ekman-Ordeberg (Danderyd, Sweden) and Stefan Hansson (Lomma, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to the use of the heparin derivative tafoxiparin in the treatment of preeclampsia (PE). The treatment may be monotherapy or combination therapy, where tafoxiparin is used in combination with an agent (drug) used as standard of care therapy in preeclampsia (PE)."
The patent was filed on Feb. 16, 2021, under Application No. 17...